What Peptides Can Compounding Pharmacies Legally Sell in 2026?

A current guide to the FDA rules that decide which peptides a compounding pharmacy may legally prepare, what the 2026 Category 2 removals did and did not change, and how to check a source before you trust it.

By Jeff Nunn. Originally published October 24, 2025. Updated July 27, 2026.

What changed in 2026:

In April the FDA removed 12 peptides from its Category 2 restricted list, including BPC-157, TB-500, KPV, MOTs-C, Semax and Epitalon, because the groups that first nominated them withdrew those nominations. On July 23 and 24 the FDA's advisory committee recommended six of the seven it reviewed for the 503A Bulks List, rejecting only emideltide (DSIP).

Neither event makes any of them legal to compound.

That sentence is the entire point of this guide, and it now has to survive a second wave of marketing that says otherwise. Removal from the restricted list is not permission. A favorable advisory recommendation is not permission either. Permission comes from placement on the 503A Bulks List, and placement requires the FDA to complete notice-and-comment rulemaking it has not yet started. For the politics, the vote margins and the panel-composition question, see our companion piece on RFK Jr.'s peptide war and the FDA. For what is and is not allowed today, read on.

Quick answers

• Are compounding pharmacy peptides legal?
• Some are. Most are not. Legality turns on whether a specific peptide is on the FDA's 503A or 503B Bulks List, is a component of an FDA-approved drug, or has an official quality standard published in the U.S. Pharmacopeia.
• Can BPC-157 be legally compounded right now?
• Replace with: No. It left the restricted Category 2 list on April 22, 2026, and the FDA's advisory committee recommended adding it on July 23, 2026. Neither event put it on the list of substances a pharmacy may compound from. That gap is the whole story.
• Are compounded peptides FDA-approved?
• No. "FDA-approved" and "legal to compound" are different statuses. Compounded drugs are never FDA-approved.
• Can I still get compounded semaglutide or tirzepatide?
• Generally no. Both shortages resolved and the temporary windows closed. Narrow exceptions exist for documented clinical need.
• What peptides can a pharmacy legally compound today?
• A short list: oxytocin, vasopressin, cosyntropin, vasoactive intestinal peptide, and GHK-Cu in non-injectable forms.
• Are compounding pharmacy peptides legal?
• Some are, most are not, and the rules moved in April 2026. Compounding pharmacies work under Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act. Together these sections create a narrow legal lane for preparing drugs that are not sold as FDA-approved products. For peptides, that lane has three gates. A peptide must clear at least one of them:

It is on the FDA's 503A Bulks List, the roster of bulk drug substances a 503A pharmacy may compound from (or its 503B equivalent), or It is a component of an FDA-approved drug (this is where the shortage exception lives), or It is the subject of a USP/NF monograph, an official quality standard in the U.S. Pharmacopeia and National Formulary.

A peptide that clears none of these three gates cannot be lawfully compounded for human use. That holds no matter who prescribes it, whether the patient consents, or how reputable the pharmacy is otherwise. The April 2026 changes did not touch this rule. What they changed is which peptides can clear gate one.

Can a pharmacy legally sell BPC-157 right now?

• As of July 27, 2026: still no, and the July advisory vote did not change it. Despite coverage that suggests otherwise, BPC-157 cannot be lawfully compounded under Section 503A today.

Here is where the confusion starts. BPC-157 sat in the FDA's Category 2 restricted list from September 2023 until April 22, 2026. On that date the FDA updated its 503A categories document to drop BPC-157 from Category 2, because the original nominators pulled their nominations. The peptide is off the restricted list. It has also not been added to the 503A Bulks List. Leaving the restricted list does not put a substance on the permitted list; those are two different actions, and only the second one makes compounding lawful.

The advisory committee's July 23 recommendation is a third event, and it is not permission either. It is advice the FDA is free to take, modify, or ignore. To actually become compoundable, BPC-157 has to be added to the 503A Bulks List, and that addition runs through a slow process: the advisory committee reviews it, the FDA decides whether to accept the recommendation, then the agency publishes a proposed rule, opens a public comment period, reviews the comments, and issues a final rule.

Under normal timelines that takes more than a year after the committee meets. The realistic earliest window for lawful BPC-157 compounding is mid-to-late 2027. Any pharmacy compounding it before then is working outside the law. The same logic applies to TB-500 and the rest of the 12 peptides that left Category 2 in April.

The two compounding lanes: 503A and 503B

The two categories serve different purposes and follow different rules.

503A covers traditional compounding pharmacies. They need a patient-specific prescription for each preparation. State boards of pharmacy handle most day-to-day oversight, with the FDA above them. When 503A conditions are met, these pharmacies are exempt from full Current Good Manufacturing Practice, the FDA's drug-manufacturing quality standard usually shortened to cGMP. Interstate shipping is capped at 5 percent of total prescriptions unless the state has a formal agreement with the FDA. They cannot mass-produce or stock for general office use.

503B covers outsourcing facilities. These register with the FDA, meet full cGMP standards, and can make larger batches for office use without an individual prescription per unit. They ship across state lines without the 5 percent cap, and they face FDA inspections and adverse-event reporting.

The two Bulks Lists are not the same. A peptide added to one is not automatically eligible under the other. That detail matters right now, because the July 2026 review is focused on the 503A side. The FDA has said little about whether the 12 peptides that left Category 2 will be considered for the 503B list. Outsourcing facilities should plan for that gap rather than assume parity.

How the FDA sorts nominated substances

Under its interim 503A policy, the FDA places nominated bulk drug substances into three working buckets:

Category 1 covers substances under review that the agency has not flagged as a significant safety risk. The FDA uses enforcement discretion here, meaning it chooses not to act against compounding while review continues, as long as the substance comes from an FDA-registered facility with a valid certificate of analysis.

Category 2 covers substances the FDA has flagged as potentially presenting significant safety risks. Enforcement discretion does not extend to them. They cannot be lawfully compounded under the interim policy.

Category 3 covers substances the FDA cannot evaluate for lack of information. They cannot be compounded either.

Current status of the disputed peptides (July 2026)

The table below reflects where each peptide in the long-running dispute stands today. The milestone column is deliberately short; for the meeting agenda, the specific indications under review, and the full procedural calendar through 2027, see the companion piece on the FDA peptide fight.

What a pharmacy can actually compound today

The list of peptides a 503A pharmacy can lawfully compound right now is short. These have been eligible for years and remain so with a valid prescription:

Oxytocin Vasopressin Cosyntropin Vasoactive intestinal peptide (VIP), a Category 1 substance under the interim policy GHK-Cu in non-injectable forms only, which the FDA is adding back to Category 1 per its May 14, 2026 update, covering topical and cosmetic preparations

Even Category 1 status does not let a pharmacy buy from a "research chemical" seller. Compounding these requires pharmaceutical-grade active ingredient from an FDA-registered facility, with a valid certificate of analysis for every lot.

The shortage exception, now closed for the GLP-1 drugs

A separate pathway, under Section 506E of the Act, lets pharmacies prepare copies of an FDA-approved drug while that drug is on the FDA's official shortage list. This was the legal basis for compounded semaglutide and tirzepatide during 2023 and 2024. Both shortages have since resolved.

As of the FDA's April 1, 2026 supply update: semaglutide is out of shortage and compounding is prohibited; tirzepatide is out of shortage and compounding is prohibited; dulaglutide injection remains in shortage, so compounding may be permissible; liraglutide injection remains in shortage, so compounding may be permissible. The lesson from the GLP-1 chapter is simple. Shortage exceptions are temporary, and once a shortage resolves the FDA moves quickly. Any pharmacy still selling compounded semaglutide or tirzepatide in mid-2026 is operating outside the law, whatever the marketing says.

The picture sharpened again on April 30, 2026, when the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound them. Liraglutide can still be compounded by a 503B facility for now, because it remains on the shortage list, but the proposal signals that large-scale compounding of these three drugs has no long-term future. The comment window on that proposal runs through late June 2026.

Restrictions that apply even when a peptide is eligible

Clearing a gate is not the end of it. Eligible compounds still carry conduct rules:

No claims of safety, efficacy, or sameness with an FDA-approved drug No "same as" or "bioidentical to" branded-product language, a rule that bites hardest in the GLP-1 space No before-and-after photos or testimonials that imply an outcome No dosing protocols or treatment guides on a pharmacy website No general weight-loss, performance, or anti-aging claims Patient-specific prescriptions for 503A work, with no office-use stockpiles Sterile-compounding standards under USP General Chapter 797, the U.S. Pharmacopeia standard for sterile preparations, for any injectable Interstate sales capped at 5 percent for 503A facilities without a state agreement A certificate of analysis for every active-ingredient lot, from an FDA-registered source.

These promotional limits will apply to the disputed peptides too, if and when they reach Category 1. There is no reason to expect a softer posture for peptide marketing than for anything else. Compounded products are also where many dosing errors that cause peptide overdose originate, since concentration and unit confusion can push patients far past the intended dose.

Enforcement in 2026

The FDA has not eased up on compounding enforcement this year. In the twelve months ending March 2026, the agency issued more than 80 warning letters to telehealth companies over misleading compounded-GLP-1 marketing. A single action on March 3, 2026 produced 30 of them. The violations cited a consistent set of problems: claims implying the product was the same as an approved drug, language that hid where the product was sourced, branded telehealth marketing of drug products without proper qualification, and efficacy claims with no basis.

The signal matters for peptides specifically, because the same framework will govern any peptide that reaches Category 1. Pharmacies and telehealth platforms eyeing the peptide space should expect close reading of their marketing language, with warning letters as a first step and stronger action for repeat or egregious cases.

Workarounds that tend to fail

The April removals set off a wave of marketing that misstated the legal status of these peptides. The July vote set off a second one. Both waves lean on the same set of workarounds, and the FDA has signaled it will pursue all of them.

"The FDA panel approved it in July." A non-binding advisory vote is not placement on the Bulks List. This is the fastest-spreading claim in the market right now.

"It came off the restricted list in April." Coming off Category 2 removed a prohibition. It did not grant permission.

"For research use only" labeling. The label does not exempt a seller from the Act when the product is marketed for human use.

Salt-form sourcing. A different counter-ion of the same molecule does not resolve the ingredient-characterization concerns the FDA raised.

Telemedicine paired with a 503A prescription. Still requires a real prescriber-patient relationship and a peptide that is actually eligible. The prescription is not the gate.

Crypto or offshore payment. Changes nothing about the legality of the compound.

"Veterinary use" labeling. Now scrutinized hard when the product flows into human-use channels.

"Same as Ozempic or Wegovy" claims. Named directly in the March 2026 warning letters.

Naturopathic or homeopathic framing. Does not exempt a product from drug-marketing rules.

The pattern holds. Every workaround tried so far has eventually drawn FDA attention, and the two newest ones are variations on the same mistake: treating a step in the process as if it were the end of it.

What this means for you right now

For patients. Do not assume your pharmacy can fill a BPC-157, TB-500, or similar prescription in 2026. Legally, it cannot. A pharmacy willing to fill one anyway is telling you something about its compliance posture. GHK-Cu in non-injectable form is the single peptide that did just get more accessible: topical creams, serums, and hair preparations using it are eligible for 503A compounding. Before you commit to any compounded peptide, check your state board of pharmacy for licensure, ask for the certificate of analysis, and confirm the active ingredient comes from an FDA-registered source.

For clinicians. Prescribing ahead of the rules, in anticipation of a change, creates compliance exposure for both you and the pharmacy, even if the pharmacy is willing. The standard process has to finish first. Beyond the common compounded peptides, some clinics also work with specialist neuropeptides, and our overview of how compounded VIP peptide is sourced explains why this form stays prescription-only and experimental.

For pharmacies and outsourcing facilities. The 503A lane is the focus of the current review; 503B is conspicuously absent, so plan separately for it. The July recommendations are your signal to start qualifying supply now rather than after a final rule, because the rulemaking gap is the only window you get to build in.Build pharmaceutical-grade ingredient supply in parallel with the rulemaking, because a finished rule without a qualified supply chain is just paperwork. And expect the promotional limits to stay strict regardless of how the list shakes out.

How to tell a legitimate compounding pharmacy from a risky one

Signals of a compliant operation: a visible state pharmacy license number, National Drug Code numbers on compounded products, membership in bodies like PCCA or the Alliance for Pharmacy Compounding, documented USP 797 sterile-compounding practice, willingness to share a certificate of analysis with HPLC testing results, a required patient-specific prescription, and no efficacy claims, dosing guides, or comparisons to branded drugs.

Red flags: dosing guides or treatment protocols on the site, before-and-after photos, "same as" branded-drug claims, "research use only" labeling paired with consumer marketing, crypto-only or offshore payment demands, and any currently restricted peptide offered for sale.

You can confirm license status directly through your state board of pharmacy.

Sources and monitoring

FDA: 503A Bulk Drug Substances

FDA: 503A Categories document, updated May 14, 2026

FDA: Substances in Compounding That May Present Significant Safety Risks

FDA: GLP-1 Compounding Policy Update, April 1, 2026

FDA: Proposed 503B Bulks List exclusion of semaglutide, tirzepatide and liraglutide, Federal Register, May 1, 2026

FDA: Telehealth warning letters, March 3, 2026

USP General Chapter 797, sterile compounding standards

Drug Quality and Security Act of 2013

FDA: Pharmacy Compounding Advisory Committee meeting materials and vote results, July 23 to 24, 2026

This guide is updated as the FDA's primary sources change.

Sourcing research compounds outside the compounding route

Compounding rules and research-chemical supplier rules are two different regulatory worlds, and the documentation standards differ accordingly. A compounding pharmacy answers to a state board. A research chemical supplier answers to nobody, which is why the certificate is the only evidence available.

For compounds that fall outside what a compounding pharmacy can legally dispense, researchers source from suppliers directly. What separates those suppliers is not whether they claim testing but what the certificates cover. Our rating methodology page sets out what we assess and publishes what each supplier we track scored against it.

Ascension Peptides publishes an 84-record searchable certificate library with four separate reports per batch, covering purity, endotoxin, heavy metals and sterility. Their code is on the Ascension Peptides coupon code page.

Limitless Biotech publishes per-batch certificates from named laboratories, including sterility and endotoxin testing to USP standards. Their code is on the Limitless Biotech coupon code page.

The peptide vendor directory lists every supplier we track with its current code and rating.

FAQ

Disclaimer:

This article is for informational and educational purposes only and does not constitute legal, medical, or professional advice. The information provided is based on FDA regulations and guidance documents current as of the publication date, but pharmaceutical compounding laws are subject to frequent changes and updates.

Not Legal Advice: This content should not be relied upon as legal counsel. Compounding pharmacies, healthcare providers, and businesses should consult with qualified legal professionals and regulatory experts before making compliance decisions.

Not Medical Advice: This article does not provide medical recommendations or endorse any specific treatments. Patients should consult with licensed healthcare providers regarding their individual medical needs and treatment options.

No Warranty: While we strive for accuracy, we make no representations or warranties regarding the completeness, accuracy, or timeliness of the information provided. Regulatory guidance can change without notice, and readers are responsible for verifying current regulations with the FDA and relevant state boards.

Use at Your Own Risk: The author and publisher assume no liability for actions taken based on the information in this article. Violation of FDA regulations can result in serious legal consequences including fines, criminal prosecution, and loss of professional licenses.

Always verify current FDA guidance, consult qualified legal and medical professionals, and review the most recent FDA Bulks Lists and shortage declarations before making any decisions related to peptide compounding.